Half-year report · HY
4578.TEDINET S100YTLB
Period2026-01-01 → 2026-06-30
Filed2026-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.33T | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.47T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.18T | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥278.5bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥242.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥285.4bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥468.0bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥226.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥215.6bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥363.1bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥173.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥218.5bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥175.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥4.40T | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥4.20T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.79T | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.09T | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.10T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.31T | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.10T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.79T | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.78T | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥3.24T | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.03T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.72T | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥469.5bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥534.6bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥411.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥426.2bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥217.1bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥403.6bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥212.7bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥173.0bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥161.6bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥130.9bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥114.3bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥137.3bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥85.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥409.07 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥685.06 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥326.12 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 73.7% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.3% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.8% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2026-01-01 → 2026-06-30 | ¥65.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥63.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2026-01-01 → 2026-06-30 | ¥6.2bn |
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥28.7bn |
| Consumer Productsreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥17.5bn |
| Consumer Productsreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥17.4bn |
| Consumer Productsreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥15m |
| Consumer Productsreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥13.8bn |
| Nutraceuticalsreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥300.1bn |
| Nutraceuticalsreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥300.1bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥16m |
| Nutraceuticalsreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥36.8bn |
| Pharmaceuticalsreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥951.6bn |
| Pharmaceuticalsreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥951.6bn |
| Pharmaceuticalsreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥250.4bn |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥1.33T |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥1.33T |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.8bn |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | ¥307.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥56.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥55.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥27.8bn |
| Consumer Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥15.8bn |
| Consumer Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥15.8bn |
| Consumer Productsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥9m |
| Consumer Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥12.9bn |
| Nutraceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥276.1bn |
| Nutraceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥276.0bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥19m |
| Nutraceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥36.7bn |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥833.8bn |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥833.8bn |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥215.4bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥1.18T |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥1.18T |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.7bn |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥269.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 797
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)東京都港区港南２－16－４ 品川グランドセントラルタワー | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)㈱阿波銀行 | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)徳島県徳島市西船場町２－24－１ | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)JP MORGAN CHASE BANK 385781（常任代理人 ㈱みずほ銀行決済営業部） | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)１ QUEEN'S ROAD CENTRAL, HONG KONG(東京都中央区日本橋３－11－１) | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)㈱りそな銀行 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区備後町２－２－１ | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)㈱メディパルホールディングス | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)東京都中央区京橋３－１－１ | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesLessThanOneUnitMember | Original text (Japanese)１単元（100株）未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)大塚ホールディングス㈱ | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)東京都千代田区神田司町２－９ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Condensed semi annual consolidated statement of financial position IFRS (text) | InterimDuration | Text · Plus | |
| Condensed semi annual consolidated statement of profit or loss IFRS (text) | InterimDuration | Text · Plus | |
| Condensed semi annual consolidated statement of comprehensive income IFRS (text) | InterimDuration | Text · Plus | |
| Condensed semi annual consolidated statement of changes in equity IFRS (text) | InterimDuration | Text · Plus | |
| Condensed semi annual consolidated statement of cash flows IFRS (text) | InterimDuration | Text · Plus | |
| Notes reporting entity condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes basis of preparation condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes significant accounting policies condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes significant accounting estimates and judgements condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes segment information condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes share capital and other equity items condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes dividends condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes revenue condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes earnings per share condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes acquisition of transcend therapeutics inc and asset acquisition of tsnd201 condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes financial instruments condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes business combinations condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes related parties condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes commitments condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Notes subsequent events condensed semi annual consolidated financial statements IFRS (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |